Navid Mokarram Dorri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Navid Mokarram Dorri has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Cécile Loaec
Institut de Cancérologie de l'Ouest, Saint Herblain, France
3 shared publications Eric Lambaudie
Institut Paoli-Calmettes
3 shared publications- Eric Lambaudie
Department of Surgical Oncology, Institut Paoli Calmettes, Marseille, France
3 shared publications - Gilles Houvenaeghel
Department of Gynecology, Hopital Européen
3 shared publications - Camille Jauffret
Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France
2 shared publications - Enora Laas
Institut Curie 5 Department of Breast, Gynecological and Reconstructive Surgery Université de Paris Cité, Paris and Saint-Cloud, France
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37
Efficacy of secondary cytoreductive surgery for relapsed ovarian low-grade serous carcinoma: a multicenter analysis from French TMRG network
To evaluate the impact of secondary cytoreductive surgery (SCS) on overall survival (OS) and progression-free survival (PFS) in patients with recurrent low-grade serous ovarian cancer. A multicenter study was conducted, including 152 patients with recurrent low-grade serous ovarian cancer treated across 31 French centers from 2002 to 2024 from the Tumeurs Malignes Rares Gynécologiques network. Patients were analyzed based on SCS status, completeness of cytoreduction (CC0 vs. CC+), and clinical outcomes. Survival analyses were performed using Kaplan-Meier estimates and Cox proportional hazards models. From 478 patients, a total of 152 patients with first recurrent low-grade serous ovarian cancer were included, with 39.5% undergoing SCS. Complete cytoreduction (CC0) was achieved in 92% of cases, with no difference in complication rates based on resection quality. After adjustment on confounding factors, SCS was independently associated with improved OS (adjusted hazard ratio on age [HRa]=0.28; 95% confidence interval [CI]=0.13-0.63; p<0.001) and showed better PFS also not statistically significant (HRa=0.57; 95% CI=0.32-1.03; p=0.06). SCS achieving complete resection significantly improves OS and appears to prolong PFS in recurrent low-grade serous ovarian cancer. Proper patient selection is critical to optimizing outcomes. These findings support the integration of SCS into the multidisciplinary management of recurrent low-grade serous ovarian cancer.
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37
Open AccessEfficacy of secondary cytoreductive surgery for relapsed ovarian low-grade serous carcinoma: a multicenter analysis from French TMRG network
To evaluate the impact of secondary cytoreductive surgery (SCS) on overall survival (OS) and progression-free survival (PFS) in patients with recurrent low-grade serous ovarian cancer. A multicenter study was conducted, including 152 patients with recurrent low-grade serous ovarian cancer treated across 31 French centers from 2002 to 2024 from the Tumeurs Malignes Rares Gynécologiques network. Patients were analyzed based on SCS status, completeness of cytoreduction (CC0 vs. CC+), and clinical outcomes. Survival analyses were performed using Kaplan-Meier estimates and Cox proportional hazards models. From 478 patients, a total of 152 patients with first recurrent low-grade serous ovarian cancer were included, with 39.5% undergoing SCS. Complete cytoreduction (CC0) was achieved in 92% of cases, with no difference in complication rates based on resection quality. After adjustment on confounding factors, SCS was independently associated with improved OS (adjusted hazard ratio on age [HRa]=0.28; 95% confidence interval [CI]=0.13-0.63; p<0.001) and showed better PFS also not statistically significant (HRa=0.57; 95% CI=0.32-1.03; p=0.06). SCS achieving complete resection significantly improves OS and appears to prolong PFS in recurrent low-grade serous ovarian cancer. Proper patient selection is critical to optimizing outcomes. These findings support the integration of SCS into the multidisciplinary management of recurrent low-grade serous ovarian cancer.
- Open Access
- 11 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Metastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
- 11 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Open AccessMetastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
- Open Access
- 5 June 2025
- Published by Wiley
Systematic ileostomy to avoid anastomotic leakage after posterior exenteration for advanced stage ovarian cancer? Retrospective cohort analysis.
Objective: To compare the rate of anastomotic leakage in patients treated with posterior pelvic exenteration for advanced ovarian cancer, regardless of whether or not a systematic ileostomy was performed.. Secondary objectives include surgical and oncologic outcomes. Method: This is an observational retrospective, multicenter study comparing two cohorts of patients managed for advanced stage ovarian cancer in two French cancer centers, from January 2019 to February 2023. All patients underwent cytoreductive surgery with colorectal resection and immediate colorectal anastomosis. Protective ileostomy could be performed in a center (center A) whereas it was never done in the other one (center B). Results: A total of 122 patients were included (54 patients in center A and 68 patients in center B). Protective ileostomy was performed in 64,9% of cases in center A. All seven anastomotic leakage concerned center B (10.3%; p=0.017). Occurrence of complications between center A and center B are similar (p=0.65). Grade 3 complications were more frequent in center B. We observed higher rate of incomplete cytoreduction in center A (p=0.04). Survival analyses do not show significative difference between center A group and center B group, for OS (p=0,32) and DFS (p=0,41). Conclusion: Performing a protective ileostomy is an effective way to prevent anastomotic leakage in cytoreduction surgery of advanced ovarian cancer. However, there is no clear evidence in term of long-term oncologic outcome and a broad policy of this procedure exposes to specific morbidity that can negatively affect the patient’s prognostic.
- 5 June 2025
- Published by Wiley
Open AccessSystematic ileostomy to avoid anastomotic leakage after posterior exenteration for advanced stage ovarian cancer? Retrospective cohort analysis.
Objective: To compare the rate of anastomotic leakage in patients treated with posterior pelvic exenteration for advanced ovarian cancer, regardless of whether or not a systematic ileostomy was performed.. Secondary objectives include surgical and oncologic outcomes. Method: This is an observational retrospective, multicenter study comparing two cohorts of patients managed for advanced stage ovarian cancer in two French cancer centers, from January 2019 to February 2023. All patients underwent cytoreductive surgery with colorectal resection and immediate colorectal anastomosis. Protective ileostomy could be performed in a center (center A) whereas it was never done in the other one (center B). Results: A total of 122 patients were included (54 patients in center A and 68 patients in center B). Protective ileostomy was performed in 64,9% of cases in center A. All seven anastomotic leakage concerned center B (10.3%; p=0.017). Occurrence of complications between center A and center B are similar (p=0.65). Grade 3 complications were more frequent in center B. We observed higher rate of incomplete cytoreduction in center A (p=0.04). Survival analyses do not show significative difference between center A group and center B group, for OS (p=0,32) and DFS (p=0,41). Conclusion: Performing a protective ileostomy is an effective way to prevent anastomotic leakage in cytoreduction surgery of advanced ovarian cancer. However, there is no clear evidence in term of long-term oncologic outcome and a broad policy of this procedure exposes to specific morbidity that can negatively affect the patient’s prognostic.
- Open Access
- 21 March 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (6) , 954-955
Rectal sparing in modified posterior exenteration: description of the technique in 10 steps
To achieve complete cytoreduction in ovarian carcinoma, rectal resection may be necessary in the case of gastrointestinal tract involvement.1 Posterior resection surgeries were described by Eiseinkopt and Bristow who modified Hudson’s pelvic peritonectomy.2
- 21 March 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (6) , 954-955
Open AccessRectal sparing in modified posterior exenteration: description of the technique in 10 steps
To achieve complete cytoreduction in ovarian carcinoma, rectal resection may be necessary in the case of gastrointestinal tract involvement.1 Posterior resection surgeries were described by Eiseinkopt and Bristow who modified Hudson’s pelvic peritonectomy.2
- Open Access
- 1 January 2021
- Published by Fortune Journals in Journal of Surgery and Research
- Vol. 04 (02) , 218-228
Comparison with 2019 of breast surgery activity and breast cancer prognostic factors in a French cancer center during the first 6 months of the COVID-19 pandemic
Introduction The rapid spread of the COVID-19 pandemic left departments of surgery, especially in oncology unprepared. The diagnostic and therapeutic management of breast cancer in Paoli Calmettes Institute cancer center underwent a major reorganization. Methods This study aimed to describe whether there was a change in the rate of surgical activity and type of tumors treated since the beginning of the outbreak (year 2020 was divided into 3 periods: before March the 17th = P1, between March the 17th and May the 11th = P2, from May the 11th to July 31st = P3) and compared to 2019. Results Over the three periods, a 12.71% decrease in the overall breast cancer surgery activity (n = 967 vs 1062) and a 18.05% decrease in new breast cancer surgery (n = 709 vs 581) was observed. The second period (P2) was the most critical one in both situations. During P2 a higher rate of large tumors, grade SBR 3 and negative endocrine receptor tumors were observed, there was also fewer Luminal A-like histological type diagnosed , during P3 fewer cT0 tumors and finally during both P2 and P3 there was a higher rate of neo-adjuvant chemotherapy. Conclusion This challenging period led to the diagnosis of higher stage and more aggressive histological types of breast cancers subsequently leading to more aggressive treatments.
- 1 January 2021
- Published by Fortune Journals in Journal of Surgery and Research
- Vol. 04 (02) , 218-228
Open AccessComparison with 2019 of breast surgery activity and breast cancer prognostic factors in a French cancer center during the first 6 months of the COVID-19 pandemic
Introduction The rapid spread of the COVID-19 pandemic left departments of surgery, especially in oncology unprepared. The diagnostic and therapeutic management of breast cancer in Paoli Calmettes Institute cancer center underwent a major reorganization. Methods This study aimed to describe whether there was a change in the rate of surgical activity and type of tumors treated since the beginning of the outbreak (year 2020 was divided into 3 periods: before March the 17th = P1, between March the 17th and May the 11th = P2, from May the 11th to July 31st = P3) and compared to 2019. Results Over the three periods, a 12.71% decrease in the overall breast cancer surgery activity (n = 967 vs 1062) and a 18.05% decrease in new breast cancer surgery (n = 709 vs 581) was observed. The second period (P2) was the most critical one in both situations. During P2 a higher rate of large tumors, grade SBR 3 and negative endocrine receptor tumors were observed, there was also fewer Luminal A-like histological type diagnosed , during P3 fewer cT0 tumors and finally during both P2 and P3 there was a higher rate of neo-adjuvant chemotherapy. Conclusion This challenging period led to the diagnosis of higher stage and more aggressive histological types of breast cancers subsequently leading to more aggressive treatments.